In our study, we only showed FLT3-ITD mutations could predict unfavorable outcome of pediatric CN-AML patients (P = 0.003), but we failed to find the relationship between NPM1 and CEBPA mutation and patients’ prognosis. The gene discussed is NPM1; the disease is acute myeloid leukemia.